Histone deacetylase inhibitor OBP‑801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1‑dependent apoptosis

Chihara,Yusuke; Iizumi,Yosuke; Horinaka,Mano; Watanabe,Motoki; Goi,Wakana; Morita,Mie; Nishimoto,Emi; Sowa,Yoshihiro; Yamada,Tadaaki; Takayama,Koichi; Sakai,Toshiyuki

doi:10.3892/ijo.2020.4969

Histone deacetylase inhibitor OBP‑801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1‑dependent apoptosis

Authors:
- Yusuke Chihara
- Yosuke Iizumi
- Mano Horinaka
- Motoki Watanabe
- Wakana Goi
- Mie Morita
- Emi Nishimoto
- Yoshihiro Sowa
- Tadaaki Yamada
- Koichi Takayama
- Toshiyuki Sakai
View Affiliations

Affiliations: Department of Molecular‑Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan, Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
Published online on: January 24, 2020 https://doi.org/10.3892/ijo.2020.4969
Pages: 848-856

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Squamous cell lung carcinoma (SQCLC) is an aggressive type of lung cancer. In contrast with the marked advances that have been achieved in the treatment of lung adenocarcinoma, there are currently no effective targeted therapies for SQCLC, for with cytotoxic drugs are still the main treatment strategy. Therefore, the present study aimed to develop novel combination therapies for SQCLC. The results demonstrated that a combined treatment with the potent histone deacetylase (HDAC) inhibitor OBP‑801 and the third‑generation anthracycline amrubicin synergistically inhibited the viability of SQCLC cell lines by inducing apoptosis signal‑regulating kinase 1 (ASK1)‑dependent, as well as JNK‑ and p38 mitogen‑activated protein kinase (MAPK)‑independent apoptosis. OBP‑801 treatment strongly induced the protein expression levels of thioredoxin‑interacting protein (TXNIP), and amrubicin treatment increased the levels of intracellular reactive oxygen species (ROS), which suggested that this combination oxidized and dissociated thioredoxin 2 (Trx2) from mitochondrial ASK1 and activated ASK1. Moreover, mouse xenograft experiments using human H520 SQCLC cells revealed that the co‑treatment potently suppressed tumor growth in vivo. These results suggested that a combined treatment with OBP‑801 and amrubicin may have potential as a therapeutic strategy for SQCLC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Ungureanu A, Zlatian O, Mitroi G, Drocas A, Ţîrcă T, Calina D, Dehelean C, Docea AO, Izotov BN, Rakitskii VN, et al: Staphylococcus aureus colonisation in patients from a primary regional hospital. Mol Med Rep. 16:8771–8780. 2017. View Article : Google Scholar : PubMed/NCBI
3	Zlatian O, Balasoiu AT, Balasoiu M, Cristea O, Docea AO, Mitrut R, Spandidos DA, Tsatsakis AM, Bancescu G and Calina D: Antimicrobial resistance in bacterial pathogens among hospitalised patients with severe invasive infections. Exp Ther Med. 16:4499–4510. 2018.PubMed/NCBI
4	Tanase A, Colita A, Ianosi G, Neagoe D, Branisteanu DE, Calina D, Docea AO, Tsatsakis A and Ianosi SL: Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant. Exp Ther Med. 12:2078–2082. 2016. View Article : Google Scholar : PubMed/NCBI
5	Călina D, Roşu L, Roşu AF, Ianoşi G, Ianoşi S, Zlatian O, Mitruţ R, Docea AO, Rogoveanu O, Mitruţ P, et al: Etiological diagnosis and pharmacotherapeutic management of parapneu-monic pleurisy. Farmacia. 64:946–952. 2016.
6	Travis WD: Pathology of lung cancer. Clin Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
7	Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, et al: A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers. Clin Cancer Res. 23:5366–5373. 2017. View Article : Google Scholar : PubMed/NCBI
8	Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, et al: Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol. 35:157–165. 2017. View Article : Google Scholar
9	Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, et al: A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol. 28:285–291. 2017. View Article : Google Scholar : PubMed/NCBI
10	Petta V, Gkiozos I, Strimpakos A and Syrigos K: Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol. 72:935–952. 2013. View Article : Google Scholar : PubMed/NCBI
11	Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, et al: Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: Development of a molecular predictive model. Mol Cancer Ther. 7:1923–1930. 2008. View Article : Google Scholar : PubMed/NCBI
12	Sun L, He Q, Tsai C, Lei J, Chen J, Vienna Makcey L and Coy DH: HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cyto-toxins via upregulating somatostatin receptor II. Am J Transl Res. 10:545–553. 2018.
13	You BR and Park WH: Down-regulation of thioredoxin1 is involved in death of calu-6 lung cancer cells treated with suberoyl bishydroxamic acid. J Cell Biochem. 117:1250–1261. 2016. View Article : Google Scholar
14	Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F and Bhatnagar A: Phase II trial of the histone deacetylase inhibitor pivaloyloxy-methyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 45:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
15	Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, et al: Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A wisconsin oncology network phase II study. J Thorac Oncol. 4:522–526. 2009. View Article : Google Scholar : PubMed/NCBI
16	Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, Dunn R and Hussain M: Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs. 30:249–257. 2012. View Article : Google Scholar
17	Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR and Belani CP: Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 28:56–62. 2010. View Article : Google Scholar
18	Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, et al: YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol. 32:545–555. 2008.PubMed/NCBI
19	Ono H, Iizumi Y, Goi W, Sowa Y, Taguchi T and Sakai T: Ribosomal protein S3 regulates XIAP expression independently of the NF-κB pathway in breast cancer cells. Oncol Rep. 38:3205–3210. 2017. View Article : Google Scholar : PubMed/NCBI
20	Salvatorelli E, Menna P, Gonzalez Paz O, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V and Minotti G: Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin. J Pharmacol Exp Ther. 341:474–483. 2012. View Article : Google Scholar : PubMed/NCBI
21	Petruccelli LA, Dupéré-Richer D, Pettersson F, Retrouvey H, Skoulikas S and Miller WH Jr: Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One. 6:e209872011. View Article : Google Scholar : PubMed/NCBI
22	You BR and Park WH: Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner. Int J Oncol. 42:359–366. 2013. View Article : Google Scholar
23	You BR, Kim SH and Park WH: Reactive oxygen species, glutathione, and thioredoxin influence suberoyl bishydroxamic acid-induced apoptosis in A549 lung cancer cells. Tumour Biol. 36:3429–3439. 2015. View Article : Google Scholar
24	Han BR, You BR and Park WH: Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. Oncol Rep. 30:2999–3005. 2013. View Article : Google Scholar : PubMed/NCBI
25	Yoshioka T, Yogosawa S, Yamada T, Kitawaki J and Sakai T: Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS. Gynecol Oncol. 129:425–432. 2013. View Article : Google Scholar : PubMed/NCBI
26	Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T and Sakai T: A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. Int J Oncol. 43:1080–1086. 2013. View Article : Google Scholar : PubMed/NCBI
27	Ono H, Sowa Y, Horinaka M, Iizumi Y, Watanabe M, Morita M, Nishimoto E, Taguchi T and Sakai T: The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway. Breast Cancer Res Treat. 171:43–52. 2018. View Article : Google Scholar : PubMed/NCBI
28	Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh Y: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:90–94. 1997. View Article : Google Scholar : PubMed/NCBI
29	Tai LM, Holloway KA, Male DK, Loughlin AJ and Romero IA: Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med. 14:1101–1112. 2010.
30	Chen YY, Liu FC, Chou PY, Chien YC, Chang WS, Huang GJ, Wu CH and Sheu MJ: Ethanol extracts of fruiting bodies of antrodia cinnamomea suppress CL1-5 human lung adenocarcinoma cells migration by inhibiting matrix metalloproteinase-2/9 through ERK, JNK, p38, and PI3K/Akt signaling pathways. Evid Based Complement Alternat Med. 2012:3784152012.PubMed/NCBI
31	Noguchi T, Takeda K, Matsuzawa A, Saegusa K, Nakano H, Gohda J, Inoue J and Ichijo H: Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem. 280:37033–37040. 2005. View Article : Google Scholar : PubMed/NCBI
32	Saxena G, Chen J and Shalev A: Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem. 285:3997–4005. 2010. View Article : Google Scholar :
33	Hatakeyama Y, Kobayashi K, Nagano T, Tamura D, Yamamoto M, Tachihara M, Kotani Y and Nishimura Y: Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy. Cancer Lett. 343:74–79. 2014. View Article : Google Scholar
34	Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
35	Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
36	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
37	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
38	Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M and Trisciuoglio D: Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer. 13:2302014. View Article : Google Scholar : PubMed/NCBI
39	Yu Y, Xing K, Badamas R, Kuszynski CA, Wu H and Lou MF: Overexpression of thioredoxin-binding protein 2 increases oxidation sensitivity and apoptosis in human lens epithelial cells. Free Radic Biol Med. 57:92–104. 2013. View Article : Google Scholar : PubMed/NCBI
40	Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq N, Paesmans M, et al: Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A phase II study Eur Respir J. 37:129–135. 2011.
41	Suzuki T, Minamide S, Iwasaki T, Yamamoto H and Kanda H: Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest New Drugs. 15:219–225. 1997. View Article : Google Scholar : PubMed/NCBI
42	Noda T, Watanabe T, Kohda A, Hosokawa S and Suzuki T: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs. 16:121–128. 1998. View Article : Google Scholar : PubMed/NCBI